Financial details of the acquisition were not disclosed. However, ZappRx raised more than $40 million from investors and sources familiar with the deal said the price was less than the amount raised in venture capital.
Allscripts may be looking to diversify beyond its core business, CNBC reports. ZappRx was founded in 2012. Today, the company is focused on helping patients access specialty medicines, including expensive and complex prescriptions.
ZappRx did not comment to CNBC about the deal.
“Allscripts is excited to add ZappRx’s platform to our growing portfolio. The specialty-prescribing space is a key focus area for Veradigm, our payer and life sciences business unit,” Allscripts said in a statement.
More articles on EHRs:
Patients who share their medical records with clinicians report higher quality care experiences
Orlando Health’s Epic program exec: 3 insights for a successful EHR implementation
EHRs can help clinicians identify patients at-risk of diabetes
